Literature DB >> 10442678

Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis.

J Oksi1, M Marjamäki, J Nikoskelainen, M K Viljanen.   

Abstract

A total of 165 patients with disseminated Lyme borreliosis (diagnosed in 1990-94, all seropositive except one culture-positive patient) were followed after antibiotic treatment, and 32 of them were regarded as having a clinically defined treatment failure. Of the 165 patients, 136 were tested by polymerase chain reaction (PCR) during the follow-up. PCR was positive from the plasma of 14 patients 0-30 months after discontinuation of the treatment, and 12 of these patients had a clinical relapse. In addition, Borrelia burgdorferi was cultured from the blood of three patients during the follow-up. All three patients belonged to the group with relapse, and two of them were also PCR positive. This report focuses on the 13 patients with clinical relapse and culture or PCR positivity. Eight of the patients had culture or PCR-proven initial diagnosis, the diagnosis of the remaining five patients was based on positive serology only. All 13 patients were primarily treated for more than 3 months with intravenous and/or oral antibiotics (11 of them received intravenous ceftriaxone, nine for 2 weeks, one for 3 weeks and one for 7 weeks, followed by oral antibiotics). The treatment caused only temporary relief in the symptoms of the patients. All but one of them had negative PCR results immediately after the first treatment. The patients were retreated usually with intravenous ceftriaxone for 4-6 weeks. None of them was PCR positive after the retreatment. The response to retreatment was considered good in nine patients. We conclude that the treatment of Lyme borreliosis with appropriate antibiotics for even more than 3 months may not always eradicate the spirochete. By using PCR, it is possible to avoid unnecessary retreatment of patients with 'post-Lyme syndrome' and those with 'serological scars' remaining detectable for months or years after infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10442678     DOI: 10.3109/07853899909115982

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  30 in total

1.  Mercury exposure as a model for deviation of cytokine responses in experimental Lyme arthritis: HgCl2 treatment decreases T helper cell type 1-like responses and arthritis severity but delays eradication of Borrelia burgdorferi in C3H/HeN mice.

Authors:  C Ekerfelt; M Andersson; A Olausson; S Bergström; P Hultman
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

2.  Evaluation of tests for Lyme disease.

Authors:  Joel Spinhirne
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

Review 3.  Lyme Borreliosis: Is there a preexisting (natural) variation in antimicrobial susceptibility among Borrelia burgdorferi strains?

Authors:  Emir Hodzic
Journal:  Bosn J Basic Med Sci       Date:  2015-07-08       Impact factor: 3.363

Review 4.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

5.  Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.

Authors:  Stephen W Barthold; Emir Hodzic; Denise M Imai; Sunlian Feng; Xiaohua Yang; Benjamin J Luft
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

6.  Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.

Authors:  Merit E Cudkowicz; Sarah Titus; Marianne Kearney; Hong Yu; Alexander Sherman; David Schoenfeld; Douglas Hayden; Amy Shui; Benjamin Brooks; Robin Conwit; Donna Felsenstein; David J Greenblatt; Myles Keroack; John T Kissel; Robert Miller; Jeffrey Rosenfeld; Jeffrey D Rothstein; Ericka Simpson; Nina Tolkoff-Rubin; Lorne Zinman; Jeremy M Shefner
Journal:  Lancet Neurol       Date:  2014-10-05       Impact factor: 44.182

7.  Delineating Surface Epitopes of Lyme Disease Pathogen Targeted by Highly Protective Antibodies of New Zealand White Rabbits.

Authors:  Artem S Rogovskyy; Salvador Eugenio C Caoili; Yurij Ionov; Helen Piontkivska; Pavel Skums; Viachaslau Tsyvina; Alex Zelikovsky; Suryakant D Waghela
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

8.  New Zealand White Rabbits Effectively Clear Borrelia burgdorferi B31 despite the Bacterium's Functional vlsE Antigenic Variation System.

Authors:  Maliha Batool; Andrew E Hillhouse; Yurij Ionov; Kelli J Kochan; Fatemeh Mohebbi; George Stoica; David W Threadgill; Alex Zelikovsky; Suryakant D Waghela; Dominique J Wiener; Artem S Rogovskyy
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

9.  Identification of Anaplasma phagocytophilum and Borrelia burgdorferi sensu lato in patients with erythema migrans.

Authors:  D Hulínská; J Votýpka; D Vanousová; J Hercogová; V Hulínský; H Drevová; Z Kurzová; L Uherková
Journal:  Folia Microbiol (Praha)       Date:  2009-08-02       Impact factor: 2.099

10.  Persistence of Borrelia burgdorferi following antibiotic treatment in mice.

Authors:  Emir Hodzic; Sunlian Feng; Kevin Holden; Kimberly J Freet; Stephen W Barthold
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.